NASDAQ:IBB iShares Biotechnology ETF (IBB) Price, Holdings, & News $149.95 -2.10 (-1.38%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$148.48 -1.47 (-0.98%) As of 10/10/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsSEC FilingsShort InterestTrendsBuy This Stock About iShares Biotechnology ETF (NASDAQ:IBB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IBB alerts:Sign Up Key Stats Today's Range$149.57▼$152.6350-Day Range$131.23▼$152.0552-Week Range$107.43▼$153.01Volume2.96 million shsAverage Volume2.14 million shsMarket Capitalization$6.21 billionAssets Under Management$6.35 billionDividend Yield0.18%Net Expense Ratio0.45%Aggregate RatingModerate Buy ETF Overview iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc. Read More iShares Biotechnology ETF ExpensesTypeIBBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.45%0.56%0.56%0.54%0.53%Other Expenses0.00%0.47%0.56%0.52%0.56%Total Expense0.45%0.75%0.76%0.73%0.73%Fee Waiver0.00%-0.67%-0.66%-0.50%-0.63%Net Expense0.45%0.60%0.63%0.63%0.60% Receive IBB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IBB ETF News HeadlinesBiotech Sector May Flip to Market Leader by Year-End (IBB)As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.September 15, 2025 | marketbeat.comDestiny Wealth Sells $8.1 Million in IBB Shares — Here's Why Biotech Stocks Are LaggingOctober 7, 2025 | fool.comBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positioned at the absolute center of this incoming capital flood— a project so fundamentally essential to the crypto ecosystem that institutional investors simply cannot ignore it. | Crypto 101 Media (Ad)IBB: Biotech's Leading Players, All In One ETFOctober 1, 2025 | seekingalpha.comThese 3 Biotech ETFs Have Gone Viral, and They All Offer Traders a CureOctober 1, 2025 | msn.comSolar, biotech, and health insurance stocks are rising on Friday: here's whyAugust 15, 2025 | msn.comSee More Headlines IBB ETF - Frequently Asked Questions How have IBB shares performed this year? iShares Biotechnology ETF's stock was trading at $132.21 at the beginning of 2025. Since then, IBB stock has increased by 13.4% and is now trading at $149.95. When did iShares Biotechnology ETF's stock split? iShares Biotechnology ETF's stock split before market open on Friday, December 1st 2017.The 3-1 split was announced on Tuesday, November 7th 2017. The newly issued shares were distributed to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Who are iShares Biotechnology ETF's major shareholders? Top institutional shareholders of iShares Biotechnology ETF include Neville Rodie & Shaw Inc. (0.10%), Toth Financial Advisory Corp (0.07%), Chesley Taft & Associates LLC (0.06%) and Marion Wealth Management (0.05%). How do I buy shares of iShares Biotechnology ETF? Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iShares Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that iShares Biotechnology ETF investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Fund Details IssueriShares Fund NameiShares Biotechnology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:IBB Inception Date2/5/2001 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkNYSE Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings254 Fund Statistics Assets Under Management$6.35 billion Average Daily Volume$2.10 million Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorJ.P. Morgan Chase Bank, N.A. AdvisorBlackRock Fund Advisors CustodianJPMorgan Chase Bank, N.A. DistributorBlackRock Investments, LLC Transfer AgentJ.P. Morgan Chase Bank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableOptionable Options Volume1,099 Put Options635 Call Options464 Short Interest10,830,000 shs Miscellaneous Outstanding Shares41,400,000Beta0.79 Creation Unit50,000 Creation Fee$614.00 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Top 10 IBB HoldingsAmgen (NASDAQ:AMGN)Holding Weight: 7.56%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 7.54%Gilead Sciences (NASDAQ:GILD)Holding Weight: 7.29%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 5.81%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 5.43%IQVIA (NYSE:IQV)Holding Weight: 3.30%argenex (NASDAQ:ARGX)Holding Weight: 3.26%Insmed (NASDAQ:INSM)Holding Weight: 3.08%Mettler-Toledo International (NYSE:MTD)Holding Weight: 2.55%Biogen (NASDAQ:BIIB)Holding Weight: 2.22%Full Holdings DetailsIBB Sector ExposureIBB Industry Exposure This page (NASDAQ:IBB) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Biotechnology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.